Clinical Trials Logo

Retinitis clinical trials

View clinical trials related to Retinitis.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06368375 Completed - Clinical trials for Retinitis Pigmentosa

Clinical and Genetic Findings in Patients With PRPF31-associated Retinitis Pigmentosa

Start date: January 1, 2023
Phase:
Study type: Observational

Retrospective chart review study to elucidate the genotype and phenotype of patients with PRPF31-associated retinitis pigmentosa and asymptomatic carriers of the respective variant(s)

NCT ID: NCT05820100 Completed - Clinical trials for Retinitis Pigmentosa

Observational Study to Assess the Reliability and Validity of the MLYMT and MLSDT

Start date: April 25, 2023
Phase:
Study type: Observational

This is a prospective Multi-Center Observational Study to assess the reliability and validity of the Multi-Luminance Y-Mobility Test (MLYMT) and Multi-Luminance Shape Discrimination Study (MLSDT) Main Outcome Measures: (i) Performance scores in normal and severely visually impaired subjects with a clinical diagnosis of retinitis pigmentosa (RP) on MLYMT and MLSDT at multiple luminance levels and (ii) reliability and content validity of MLYMT and MLSDT.

NCT ID: NCT05800301 Completed - Clinical trials for Retinitis Pigmentosa

Management of Retinitis Pigmentosa Via Combination of Wharton's Jelly-derived Mesenchymal Stem Cells and Magnovision

Start date: January 1, 2019
Phase: Phase 3
Study type: Interventional

Purpose To investigate whether the natural progression rate of retinitis pigmentosa (RP) can be decreased with subtenon umbilical cord Wharton's jelly derived mesenchymal stemcell (WJ-MSC) application alone or combination with retinal electromagnetic stimulation (rEMS). Material and methods The study included prospective analysis of 130 eyes of 80 retinitis pigmentosa patients with a 36-month follow-up duration. Patients constitute 4 groups with similar demographic characteristics. The subtenon WJ-MSC only group consisted of 34 eyes of 32 RP patients as Group1; The rEMS only group consisted of 32 eyes of 16 RP patients as Group2; The combined management group consisted of 32 eyes of 16 RP patients who received combined WJ-MSC and rEMS as Group3; The natural course (control) group consisted of 32 eyes of 16 RP patients who did not receive any treatment were classified as Group4. Fundus autofluorescence surface area (FAF-field), horizontal and vertical ellipsoid zone width (EZW), fundus perimetry deviation index (FPDI), full field electroretinography magnitude (ERG-m) and best corrected visual acuity (BCVA) changes were compared within and between groups after 36 month follow up period.

NCT ID: NCT05712148 Completed - Clinical trials for Retinitis Pigmentosa

Spheroidal Mesenchymal Stem Cells in Retinitis Pigmentosa

Start date: October 11, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

Purpose: This prospective clinical case series aimed to evaluate the effect of suprachoroidal implantation of mesenchymal stem cells (MSCs) in the form of spheroids as a stem cell therapy for retinitis pigmentosa (RP) patients with relatively good visual acuity. Methods: Fifteen eyes of 15 patients with RP who received suprachoroidal implantation of MSCs in the form of spheroids were included. Best corrected visual acuity (BCVA), 10-2 and 30-2 visual field examination and multifocal electroretinography (mfERG) recordings were recorded at baseline, postoperative first, third- and sixth-months during follow-up.

NCT ID: NCT05392179 Completed - Clinical trials for Retinitis Pigmentosa

A Study in Subjects With Retinitis Pigmentosa

Start date: July 14, 2022
Phase: Phase 2
Study type: Interventional

An open-label Phase II clinical trial, 8 (eight) subjects with retinitis pigmentosa due to rhodopsin mutations (including P23H) will be identified and treated with serial intravitreal injections of ADX-2191 in the worse seeing eye. Ocular structure and function will be evaluated.

NCT ID: NCT05285618 Completed - Clinical trials for Retinitis Pigmentosa

The Perceptual Experience of Argus II Users

Start date: January 11, 2022
Phase: N/A
Study type: Interventional

The goal of this project is to quantify and computationally model the perceptual experiences of Argus II retinal prosthesis patients. The investigators will produce visual percepts in patients either by directly stimulating electrodes or by asking them to view a computer or projector screen and using standard FDA-approved stimulation protocols (as is standardly used for their devices) to convert the computer or projector screen image into pulse trains on their electrodes. Performance of patients will be compared to that of sighted control subjects viewing a simulation of the vision generated by Argus II in virtual reality.

NCT ID: NCT04983914 Completed - Clinical trials for Retinitis Pigmentosa

Retrospective NIS to Evaluate the Patient Benefit of TES

Start date: September 6, 2021
Phase:
Study type: Observational

In this retrospective non-interventional study (NIS), the subjective and objective benefit of patients with retinitis pigmentosa (and other dystrophies like Usher, Choroideremia or cone-rod dystrophy), who have been prescribed the therapy of transcorneal electrostimulation (TcES) with the OkuStim System, is assessed.

NCT ID: NCT04945772 Completed - Clinical trials for Retinitis Pigmentosa

Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]

RESTORE
Start date: July 13, 2021
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the safety and efficacy of a single intravitreal injection of virally-carried Multi-Characteristic Opsin (MCO-010).

NCT ID: NCT04926129 Completed - Clinical trials for X-Linked Retinitis Pigmentosa

Natural History of the Progression of X-Linked Retinitis Pigmentosa

XOLARIS
Start date: September 13, 2017
Phase:
Study type: Observational

The objective of the study is to gain a better understanding of disease progression over time in participants with X-linked retinitis pigmentosa (XLRP).

NCT ID: NCT04925687 Completed - Clinical trials for Retinitis Pigmentosa

Phase 1 Study of Intravitreal Autologous CD34+ Stem Cell Therapy for Retinitis Pigmentosa

BMSCRP1
Start date: June 1, 2021
Phase: Phase 1
Study type: Interventional

In this Phase 1 open-labeled prospective study, one eye of each participant with vision loss from retinitis pigmentosa will be administered intravitreal injection of autologous CD34+ stem cells harvested from bone marrow. Each participant will be examined serially for 6 months after study injection to determine safety and feasibility of this intervention.